Travere Therapeutics (TVTX) Jefferies Global Healthcare Conference 2025 summary

Strategic focus and pipeline overview

• Focused on rare diseases, with key programs in IgA nephropathy, FSGS, and classical homocystinuria (HCU).

• FILSPARI launched for IgA nephropathy, aiming to become foundational therapy.

• FSGS program has a PDUFA date in January next year; phase 3 HCU enrollment to begin next year.

Regulatory and clinical updates

• FDA accepted the supplemental NDA for FSGS and plans an advisory committee, likely to focus on proteinuria as a surrogate endpoint.

• PARASOL initiative supports proteinuria as a validated endpoint; FDA feedback aligns with this approach.

• EMA is engaged but less involved than FDA; partners are working to define the EU regulatory path.

• Orphan drug exclusivity expected to extend to 2033, with potential for additional pediatric exclusivity.

Market opportunity and commercial strategy

• FSGS affects over 30,000 U.S. patients not on dialysis; FILSPARI shows ~50% reduction in proteinuria and potential for complete remission.

• Rapid uptake anticipated due to high unmet need and lack of approved therapies.

• Majority of addressable patients are biopsy-confirmed; genetic testing is increasing but remains limited.

• FILSPARI launch in IgA nephropathy exceeded 700 new patient start forms per quarter, with high compliance and persistence.